The protein and enzyme inhibitors are the most experimental but the most exciting new drug therapies for follicular lymphoma and other lymphomas. Macetinostat, formerly known as MGCD0103, is one of these.
Phase II studies in patients with multiple types of lymphoma were going on in 2009 when they were halted because of some heart complications. They restarted and presented results in 2010. Among the 28 follicular lymphoma patients (all with advanced, relapsed disease), there was an 11% response rate and no complete remissions. About 4% of lymphoma patients (and 9% of Hodgkin's disease patients) had heart-related side effects, which was much higher than the rate for patients with solid tumours. More research into toxicity will be needed before this drug becomes a viable therapeutic choice.
Published Studies
R.E. Martell et al. "Phase II Study of MGCD0103 in Patients with Relapsed Follicular Lymphoma." Journal of Clinical Oncology (2010).
No comments:
Post a Comment